Literature DB >> 21401392

Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma.

Eliza M Raymundo1, Michael E Lipkin, Lionel B Bañez, John G Mancini, Dorit E Zilberman, Glenn M Preminger, Brant A Inman.   

Abstract

INTRODUCTION: Upper tract urothelial carcinoma (UT-UC) is an uncommon disease with pronounced difference in 5-year survival for noninvasive (96%) versus invasive (17%) disease. High survival rate of early disease questioned the accepted norm of using radical nephroureterectomy (RNU) for all stages. This review assesses effectiveness of endoscopic management for UT-UC.
METHODS: A review of 131 UT-UC patients seen between January 1999 and October 2009 was performed. Demographic, clinicopathologic, and outcomes data were collected and compared between patients initially managed with RNU versus those initially managed with nephron-sparing surgery (NSS). The chi-square or Fisher's exact tests for categorical variables and the Wilcoxon-Mann-Whitney test for continuous variables were used. Clinical and pathologic stages of RNU patients were evaluated with chi-square testing, whereas difference in length of stay was detected using linear regression. Recurrence rates were compared using multivariate Cox regression.
RESULTS: The two arms had similar distributions of age, sex, frequency of medical comorbidities, American Society of Anesthesiologists (ASA), and Charlson scores. Mean-adjusted length of stay was 2.1 (95% confidence interval [1.6, 2.5]) and 5.5 days (95% confidence interval [5.3, 6.4]) for the NSS and RNU groups, respectively (p < 0.001). Comparison of clinical and pathologic stages of RNU patients showed a difference (p < 0.001), with under-staging noted in 32%. Men (Hazards Ratio = 2.9 [1.5-5.5], p = 0.001) and NSS patients (hazards ratio [HR] = 3.5 [1.7-7.3], p < 0.001) had threefold increased recurrence risk.
CONCLUSION: NSS offered shorter hospital stay but had increased risk of recurrence. Therefore, extreme care should be made to rule out occult invasive tumors preoperatively. Patients being managed endoscopically must be informed of the necessity for close follow-up.

Entities:  

Mesh:

Year:  2011        PMID: 21401392     DOI: 10.1089/end.2010.0276

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  12 in total

1.  Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma.

Authors:  Anil Kapoor; Christopher B Allard; Peter Black; Wassim Kassouf; Christopher Morash; Ricardo Rendon
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

2.  Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.

Authors:  Michael Metcalfe; Gavin Wagenheim; Lianchun Xiao; John Papadopoulos; Neema Navai; John W Davis; Jose A Karam; Ashish M Kamat; Christopher G Wood; Colin P Dinney; Surena F Matin
Journal:  J Endourol       Date:  2017-07-21       Impact factor: 2.942

Review 3.  [Instillation therapies for urothelial carcinoma of the upper urinary tract].

Authors:  P Bosshard; G N Thalmann; B Roth
Journal:  Urologe A       Date:  2019-01       Impact factor: 0.639

Review 4.  Results and outcomes after endoscopic treatment of upper urinary tract carcinoma: the Austrian experience.

Authors:  Harun Fajkovic; Tobias Klatte; Udo Nagele; Michael Dunzinger; Richard Zigeuner; Wilhelm Hübner; Mesut Remzi
Journal:  World J Urol       Date:  2012-09-27       Impact factor: 4.226

Review 5.  Risk-adapted strategy for the kidney-sparing management of upper tract tumours.

Authors:  Thomas Seisen; Pierre Colin; Morgan Rouprêt
Journal:  Nat Rev Urol       Date:  2015-02-24       Impact factor: 14.432

6.  Conservative nephron-sparing treatment of upper-tract tumors.

Authors:  Paul Smith; Juliette Mandel; Jay D Raman
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

7.  Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer.

Authors:  Shih Ya Hung; Wen Chou Yang; Hao Lun Luo; Chun-Chien Hsu; Yen Ta Chen; Yao Chi Chuang
Journal:  Int Urol Nephrol       Date:  2013-11-08       Impact factor: 2.370

Review 8.  Future strategies to enhance kidney preservation in upper urinary tract urothelial carcinoma.

Authors:  Meredith Metcalf; Phillip M Pierorazio
Journal:  Transl Androl Urol       Date:  2020-08

9.  Endoscopic management versus radical nephroureterectomy for localized upper tract urothelial carcinoma in a high endemic region.

Authors:  Cheng Kuang Yang; Yao Chou Tsai; Yung-Tai Chen; Chih-Chin Yu; Hsin-Chih Yeh; Hsiang-Ying Lee; Yuan-Hong Jiang; Yu-Khun Lee; Chia-Hao Kuei; Chia-Chang Wu; Chao-Yuan Huang; Wei-Yu Lin
Journal:  Sci Rep       Date:  2021-02-17       Impact factor: 4.379

Review 10.  Upper urinary tract disease: what we know today and unmet needs.

Authors:  Romain Mathieu; Karim Bensalah; Ilaria Lucca; Aurélie Mbeutcha; Morgan Rouprêt; Shahrokh F Shariat
Journal:  Transl Androl Urol       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.